SAFETY OF ABT-450/R/OMBITASVIR + DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS: RESULTS FROM PEARL II, PEARL III, AND PEARL IV

Richard Aspinall  1     Jacob Lalezari  2     Yan Luo  3     Ronald Pruitt  4     Velimir Luketic  5     Giovanni Gaeta  6     Iwona Olszok     William King     Selim G├╝rel     Yiran Hu     Jeffrey Enejosa     Daniel E. Cohen     Nancy Shulman    
1 Queen Alexandra Hospital, Portsmouth, United Kingdom
2 Quest Clinical Research, San Francisco, United States
3 Abbvie Inc., North Chicago, United States
4 Nashville Gastrointestinal Specialists, Inc./nashville Medical Research Institute, Nashville, United States
5 Virginia Commonwealth University, Richmond, United States
6 A.o.u. Seconda

Conference
UEG Week 2014

Citation
United European Gastroenterology Journal; 2014: 2 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing